COVID-19 vaccines require two doses at specific intervals to induce adequate immunity
the verdict
SUPPORTED
the evidence backs this
confidence 98/100
Clinical trials and subsequent evaluations consistently demonstrate that standard COVID-19 vaccines require a primary two-dose regimen, administered at specified intervals, to achieve adequate humoral immunity and optimal clinical efficacy.
Evidence for · 4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · cited by 5,024
Evaluates efficacy based primarily on a two-dose vaccine regimen.
See more details
More for · 3
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
2020 · cited by 2,621
Demonstrates that antibody and neutralising responses are boosted significantly following a second dose.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
2021 · cited by 1,210
Confirms efficacy findings based on standard two-dose administration intervals.
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls
2021 · cited by 135
Assesses vaccine effectiveness and antibody responses specifically following the recommended two-dose vaccination schedule.